Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-04-13
2010-06-08
Desai, Anand U (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S326000
Reexamination Certificate
active
07732411
ABSTRACT:
The present invention relates to a method for promoting cardiac tissue repair comprising administering to the cardiac tissue a therapeutically effective amount of an angiogenic thrombin derivative peptide and/or inhibiting or reducing vascular occlusion or restenosis. The invention also relates to methods of stimulating revascularization. In yet another embodiment, the invention relates to the use of thrombin derivative peptides in the manufacture of a medicament for the methods described herein.
REFERENCES:
patent: 5244460 (1993-09-01), Unger et al.
patent: 5352664 (1994-10-01), Carney et al.
patent: 5500412 (1996-03-01), Carney et al.
patent: 5912229 (1999-06-01), Thim et al.
patent: 6033436 (2000-03-01), Steinke et al.
patent: 6191113 (2001-02-01), Nakahara et al.
patent: 6197751 (2001-03-01), Malinda et al.
patent: 6363938 (2002-04-01), Saadat et al.
patent: 6861407 (2005-03-01), Carney
patent: 6867190 (2005-03-01), Carney
patent: 7034001 (2006-04-01), Carney
patent: 7214661 (2007-05-01), Carney
patent: 2002/0061852 (2002-05-01), Carney
patent: 2002/0187933 (2002-12-01), Carney
patent: WO 88/03151 (1988-05-01), None
patent: WO 94/25056 (1994-11-01), None
patent: WO 99/53943 (1999-10-01), None
patent: WO 00/24412 (2000-05-01), None
patent: WO 02/04008 (2002-01-01), None
Hendel, R.C., et al., “Effect of Intracoronary Recombinant Human Vascular Endothelial Growth Factor on Myocardial Perfusion,”Journal of The American Heart Association, 101(2):118-121, (2000).
Aoki, M., et al., “Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets,”Gene Therapy, 7(5):417-427, (2000).
Pecher, P., and Schumacher, B.A., “Angiogenesis is Ischemic Human Myocardium: Clinical Results After 3 Years,”The Annals of Thoracic Surgery, 69(5):1414-1419, (2000).
Kawasuji, M., et al., “Therapeutic Angiogenesis With Intramyocardial Administration of Basic Fibroblast Growth Factor,”The Annals of Thoracic Surgery, 69(4):1155-1161, (2000).
Rosengart, T.K., et al., “Six-Month Assessment of a Phase I Trial of Angiogenic Gene Therapy for the Treatment of Coronary Artery Disease Using Direct Intramyocardial Administration of an Adenovirus Vector Expressing the VEGF121 cDNA,”Annals of Surgery, 230(4):466-472, (1999).
Laham, R.J., et al., “Intracoronary and Intravenous Administration of Basic Fibroblast Growth Factor: Myocardial and Tissue Distribution,”Drug Metabolism and Disposition, 27(7):821-826, (1999).
Sellke, F.W., et al., “Therapeutic Angiogenesis With Basic Fibroblast Growth Factor: Technique and Early Results,”The Annals of Thoracic Surgery, 65(6):1540-1544, (1998).
Folkman, J., “Angiogenic Therapy of the Human Heart,”Journal of The American Heart Association, 97(7):628-629, (1998).
McKenna, C.J., et al., “Selective ETAReceptor Antagonism Reduces Neointimal Hyperplasia in a Porcine Coronary Stent Model,”Journal of The American Heart Association, 97(25):2551-2556, (1998).
Frimerman, A., et al., “Chimeric DNA-RNA Hammerhead Ribozyme to Proliferating Cell Nuclear Antigen Reduces Stent-Induced Stenosis in a Porcine Coronary Model,”Journal of The American Heart Association, 99(5):697-703, (1999).
Voisard, R., et al., “High-dose diltiazem prevents migration and proliferation of vascular smooth muscle cells in various in-vitro models of human coronary restenosis,”Coronary Artery Disease, 8(3/4):189-201, (1997).
Nadir, M., et al., “Inhibition of coronary restenosis by antithrombin III in atherosclerotic swine,”Coronary Artery Disease, 7(11):851-861, (1996).
Munro, E., et al., “Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis,”European Journal of Clinical Investigation, 24(11):766-772, (1994).
Chen, S.J., et al., “Mithramycin Inhibits Myointimal Proliferation After Balloon Injury of the Rat Carotid Artery In Vivo,”Circulation, 90(5):2468-2473, (1994).
Shi, Y., et al., “Downregulation of c-mycExpression by Antisense Oligonucleotides Inhibits Proliferation of Human Smooth Muscle Cells,”Circulation, 88(3):1190-1195, (1993).
Speir, E., and Epstein, S.E., “Inhibition of Smooth Muscle Cell Proliferation by an Antisense Oligodeoxynucleotide Targeting the Messenger RNA Encoding Proliferating Cell Nuclear Antigen,”Circulation, 86(2):538-547, (1992).
Stiernberg, J., et al., “The Role of Thrombin and Thrombin Receptor Activating Peptide (TRAP-508) in Initiation of Tissue Repair,”Thrombosis and Haemostasis, 70(1):158-162, (1995).
Carney, D.H., et al., “Enhancement of Incisional Wound Healing and Neovascularization in Normal Rats by Thrombin and Synthetic Thrombin Receptor-activating Peptides,”J. Clin. Invest., 89:1469-1477, (1992).
Carney, D.H., et al., “Role of High-Affinity Thrombin Receptors in Postclotting Cellular Effects of Thrombin,”Seminars in Thrombosis and Hemostasis, 18(1):91-102, (1992).
Stiernberg, J., et al., “Acceleration of full-thickness wound healing in normal rats by the synthetic thrombin peptide, TP508,”Wound Repair and Regeneration, 8(3):204-215, (2000).
Glenn, K.C., et al., “Synthetic Peptides Bind to High-Affinity Thrombin Receptors and Modulate Thrombin Mitogenesis,”Peptide Research, 1(2):65-73, (1988).
Sower, L.E., et al., “Thrombin Peptide, TP508, Induces Differential Gene Expression in Fibroblasts through a Nonproteolytic Activation Pathway,”Experimental Cell Research, 247:422-431, (1999).
Carney, D.H., “Postclotting Cellular Effects of Thrombin Mediated by Interaction with High-Affinity Thrombin Receptors,”Thrombin: Structure and Function, Chapter 10, pp. 351-396, (1992).
Norfleet, A.M., et al., “Thrombin Peptide, TP508, Stimulates Angiogenic Responses in Animal Models of Dermal Wound Healing, in Chick Chorioallantoic Membranes, and in Cultured Human Aortic and Microvascualr Endothelial Cells,”Gen. Pharmacology35:249-254 (2002).
Tsopanoglou, N.E., and Maragoudakis, M.E., “On the Mechanism of Thrombin-induced Angiogenesis,”J. Biol. Chem., 274(34):23969-23976 (1999).
Coleman, C.L., et al., “Systemic Injection of Thrombin Peptide TP508 Mitigates Angioplasty-related Restenosis in Hypercholesterolemic Rabbit Iliac Arteries,” Abstract LB14, Presented at the Experimental Biology 2001 Meeting (Orlando, Florida).
Naldini, A., et al., “Thrombin Regulates the Expression of Proangiogenic Cytokines via Proteolytic Activation of Protease-Activated Receptor-1,”Gen. Pharmacology35:255-259 (2002).
Davis Steven G.
Desai Anand U
Foley & Lardner LLP
Orthologic Corp.
LandOfFree
Methods of therapy with thrombin derived peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of therapy with thrombin derived peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of therapy with thrombin derived peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4204698